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Patients (pts) with HR-MM are in need of new strategies
for relapse prevention due to high risk of treatment failure.
AlloHCT is an attractive treatment that relies on graft-versus-
myeloma to control the disease. Reduced intensity condi-
tioning alloHCT is associated with low transplant-related
mortality (TRM), broadening this approach to patients with
MM. However, MM progression remains a frequent cause of
treatment failure. Maintenance therapy may potentially
improve outcomes. The primary objective of this study was
to determine the tolerability and safety of lenalidomide
maintenance (Len) for 1 year post-alloHCT in pts with HRMM
deﬁned as: relapsed after autologous HCT and/or plasma-
blastic morphology >2%, b2M  5.5 mg/L, hypodiploidy, del
13 by standard karyoptyping, t(4;14), t(14;16) or del 17p.
Patients who experienced >3 progressions prior to alloHCT,
progressed or relapsed after alloHCT, had grade 3 graft-
versus-host disease (GVHD), on >10 mg/day (d) prednisone,
or with fallen donor chimerism prior to Len were excluded.
The starting dose of Len was 10 mg/d for 21 of 28d per cycle
with monthly dose escalation by 5 mg increments to
a maximum of 25 mg/d. Dose reduction to 5 mg/d and 5 mg
on alternating days (qod) was allowed to control for toxicity.
Thirty patients who received reduced intensity conditioning
were enrolled, with a median age of 54 (range 38-68), 57%
achieved very good partial response (VGPR) or better prior to
Len, 40% had unrelated donors and 97% received peripheral
blood grafts. The median time from alloHCT to Len was 96d
(range 66-171). Among 29 evaluable patients, a total of 200
cycles were initiated and 177were completed, with 45% at 10
mg/d, 17% at 5 mg/d and 21% at 5 mg qod. 17% of patients
received >10 mg/d. 8 patients terminated maintenance
during the ﬁrst cycle, and 10 (34%) completed treatment.
Reasons for maintenance discontinuation were acute GVHD
(37%), MM progression (33%), neutropenia (10%), skin rash
(10%) and infection (10%). Grade 3-4 neutropenia was the
most common reason for lowering dose or interruptingcycles. Complete response (CR) was the best response of 55%
of pts, and 4 of 14 pts not in CR at the start of maintenance
achieved CR after 2-5 cycles. Cumulative incidence of MM
progression from start of maintenance was 28% (95% CI, 12-
48%), TRM was 3% (0-12%) and grades 3 acute GVHD was
17% (6-33%). 12-month probabilities of progression-free
(PFS) and overall survival from initiation of Len were 68%
(95% CI 46-83%) and 88% (95% CI 67-96%). Despite Len being
completed in only 34% of pts, this drug appears to be
generally well tolerated although dose reductions were
frequently required due to neutropenia. Lowering starting
doses and growth factor support should be considered when
using Len in this setting. Survival outcomes observed in this
study suggest a beneﬁt of maintenance therapy in pts with
HRMM after alloHCT.81
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Patients with lymphoid malignancies who relapse after
autologous hematopoietic cell transplantation (HCT) have
few curative treatment options. Allogeneic HCT using full
dose conditioning can cure selected patients but high non-
relapse mortality (NRM) limits its broad applicability. We
developed reduced intensity conditioning for allogeneic HCT
with total lymphoid irradiation and rabbit anti-thymocyte
globulin (TLI-ATG) that was safe, well tolerated, protected
against GVHD and allowed for retained graft-versus tumor
reactions. We report the outcomes of 47 consecutive patients
with lymphoid malignancies who relapsed after auto-HCT
and received TLI-ATG conditioning followed by the infusion
of G-mobilized allografts. Included were 29 (62%) patients at
high risk of relapse because the disease failed to achieve
remission with salvage therapy prior to TLI-ATG, 20 (43%)
patients with relapse within 18 months of their auto-HCT,
and 22 (47%) patients at high risk of developing GVHD due to
the lack of fully HLA-matched related donor. 26 patients had
B-cell NHL (diffuse large B-NHL (n¼19), mantle cell
lymphoma (n¼4) or other subtypes (n¼3)) all of whom
received prior rituximab, 6 patients had T cell NHL, and 15
had Hodgkin lymphoma. The TLI-ATG regimen was well
tolerated and 46 (98%) patients received their graft infusion
as an outpatient. The hospital readmission rate in the ﬁrst
100 days was 28% (n¼13). Only 13 (28%) and 4 (9%) patients
